The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Procrastination isn’t laziness. It is overwhelm, avoidance, and the human brain trying to dodge discomfort. With tiny steps, ...

Based on developmental psychology and Nietzsche, here's how people become trapped in patterns of appeasement, rebellion, or ...

Let's look at the pros and cons of going full AI to help you understand how the value and purpose of software development ...

Why we procrastinate has less to do with willpower than with how flexibly our brains handle stress and discomfort - and the ...

For companies to survive the AI disruption, leaders must cultivate a resilient, adaptive ecosystem. Inclusivity is key to ...

One of the earliest mentions of New Year's resolutions appeared in a Boston newspaper in 1813. But the practice itself can be ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...